Introduction
The c-Myc oncoprotein has been found to be overexpressed in a wide variety of tumor types as a result of several mechanisms including gene ampli®cation, translocation and point mutation (Cole, 1986; DallaFavera et al., 1982; Lee et al., 1996) . The importance of c-Myc in tumorigenesis has been demonstrated in various experimental studies. Co-transfection of c-myc and ras in rat embryo ®broblasts induces a transformed phenotype and produces tumors when cells are injected in nude mice (Land et al., 1983) . Overexpression of c-Myc in transgenic mice results in an increased tumor formation, which is greatly enhanced by co-expression of Ras (Sinn et al., 1987) . It has recently been demonstrated that c-Myc-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2 (D'Cruz et al., 2001) . The mechanisms by which c-Myc participates in tumorigenesis are not yet completely understood. Identi®cation of c-Myc targets, which regulate cell growth, both positively and negatively, may in part explain the role of c-Myc in controlling cell proliferation. In particular, c-Myc has been shown to enhance transcription of a-prothymosin (Eilers et al., 1991) , ornithine decarboxylase (Bello-Fernandez et al., 1993) , lactate dehydrogenase-A (Shim et al., 1997) , cdc25A (Galaktionov et al., 1996) and MrDb (Grandori et al., 1996) and to repress the transcription of the growth arrest genes gas1 (Lee et al., 1997) and gadd45 (Littlewood et al., 1995) .
The c-myc oncogene has also been implicated in the regulation of telomerase through transcriptional activation of telomerase reverse transcriptase, the limiting component for telomerase activity (Wang et al., 1998; Wu et al., 1999; Kyo et al., 2000; Greenberg et al., 1999a; Weinrich et al., 1997; Bodnar et al., 1998; Vaziri and Benchimol, 1998) . Numerous studies have demonstrated that the human telomerase reverse transcriptase (hTERT) is expressed in most malignant tumors but not in normal non-proliferating tissues (Shay and Bacchetti, 1997) and that expression of hTERT re¯ects that of telomerase activity (Nakamura et al., 1997; Meyerson et al., 1997) . In addition, whereas ectopic expression of hTERT in normal cells results in telomere maintenance and life-span extension (Bodnar et al., 1998; Vaziri and Benchimol, 1998) , inhibition of the enzyme in immortal and tumor cells is lethal, demonstrating a key role for hTERT in cell immortalization and tumorigenesis (Zhang et al., 1999; Hahn et al., 1999b) . A link between Myc expression and telomerase activity has been observed. In particular, N-myc gene has been noted to be associated with high telomerase activity in neuroblastoma (Hiyama et al., 1995) and the same expression pro®le has been found during mouse erytroleukemia cell dierentiation (Greenberg et al., 1998) .
Here, we investigated the role of telomerase function in the c-Myc-dependent tumorigenicity of human melanoma cells. To this purpose M14 parental line, M14-derived c-Myc low-expressing clones previously obtained (Biroccio et al., 2001) , and c-Myc lowexpressing clones up-regulating either wild-type (wt) or mutant (mt) hTERT, were used.
Results

c-Myc down-regulation decreases M14 cell proliferation and tumorigenic ability
The parental M14 human melanoma cell line, the MN2 control clone and the MAS51, MAS53 and MAS57 cMyc low-expressing clones, were employed (Biroccio et al., 2001) . As shown in Table 1 , the amount of c-Myc protein in MAS51, MAS53 and MAS57 cells is about eight times lower than in the M14 parental line or the MN2 control clone. As expected, c-Myc downregulation altered the in vitro growth behavior of the cells. The proliferation rate of the c-Myc lowexpressing clones was signi®cantly reduced, the doubling time of this population being about 45 vs 20 h for M14 or MN2 cells. Similarly, the cells had reduced cloning eciency (about 15 vs 40% for control lines) and increased rate of apoptosis with about 45% of apoptotic cells vs less than 5% in the control lines, evaluated at day 6 of culture.
The M14 parental line, the MN2 control clone and the c-Myc transfectants were also injected in nude mice and their tumorigenicity evaluated (Table 1) . With an inoculum of 1610 6 M14 or MN2 cells, tumors developed in all the animals (12 out of 12). In contrast, only 33% of mice had tumors following injection of 1610 6 c-Myc low-expressing cells. The median time of tumor appearance for the control cell lines was about 9 days vs about 35 days for cells expressing low c-Myc levels. Thus, down-regulation of c-Myc is associated with a reduction of growth rate and tumorigenic capacity in vivo, and with an increase in apoptosis.
c-Myc down-regulation is accompanied by reduced telomerase activity and telomere length To evaluate hTERT mRNA expression upon c-Myc down-regulation, RT ± PCR with hTERT-speci®c primers, was performed in the MAS51, MAS53 and MAS57 clones and control cell lines. As illustrated in Figure 1A , c-Myc down-regulation led to a three times reduction in hTERT mRNA levels. To determine whether this reduction correlated with lower telomerase activity, semi-quantitative TRAP assay was performed. To de®ne the sensitivity of the method and the semiquantitative relationship between protein concentration and ladder band intensity, dierent amounts of M14 cell extract (from 0.1 to 2 mg of total proteins) were used to choose the appropriate protein concentration that produced a linear response. As shown in Figure  1B , telomerase activity was repressed in the MAS51, MAS53 and MAS57 by about seven times compared to the control cells. ITAS was ampli®ed to the same extent in all cell lines, excluding the presence of Taq polymerase inhibitors in the c-Myc transfectants.
To examine whether dierence in telomere length existed between the control cells and the c-Myc transfectants, Terminal Restriction Fragment (TRFs) were measured by Southern blot using the (TTAGGG) 3 probe ( Figure 1C ). In M14 and MN2 control cells, TRFs length ranged from about 12 to 4 kb, with a mean length of about 8 kb. In contrast, TRFs in the MAS51, MAS53 and MAS57 clones were signi®cantly shorter, ranging from 6.5 to 1.5 kb with a mean length of about 4 kb.
Up-regulation of hTERT promotes cell proliferation of the c-Myc low-expressing clones Two c-Myc low-expressing clones (MAS51 and MAS53) were infected with amphotropic viruses encoding wt hTERT, mt hTERT-HA, or only the drug resistance marker. After drug selection, wt hTERT and control virus-infected cells were analysed at early and late culture passages, while the hTERT-HA-infected cells were analysed only at late passages. Figure 2A shows that telomerase activity was increased The median latency of tumor appearance in MAS51, MAS53 and MAS57 c-Myc low-expressing clones was calculated on four mice which developed tumors by infection with wt or mt hTERT-encoding viruses, compared to control virus-infected cells. Levels of activity were similar in the wt hTERT-infected cells regardless of time in culture (MAS51/T E , MAS53/T E , MAS51/T L and MAS53/T L ) and in the mt hTERT-HA-infected cells (MAS51/T-HA L and MAS53/T-HA L ). On the contrary, signi®cant dierence in TRF length was detected with time among cell lines ( Figure  2B ). As expected, cells infected with the control of hTERT-HA viruses, or infected with the wt hTERT virus and analysed at early passage, had TRFs comparable in length to those of uninfected cells (see Figure 1 ). On the other hand, in cells infected with the latter virus but analysed at late passage, TRFs length was similar to that of the parental M14 line, demonstrating that up-regulation of wt telomerase leads to telomere lengthening upon cell growth. The fact that this lengthening did not occur in hTERT-HAinfected cells con®rms that the HA-tagged protein is biologically inactive.
To evaluate whether restoration of telomerase in the c-Myc low-expressing clones promoted cell proliferation, cell cycle analysis was performed by pulse-labeling cells with BrdU, and the progression of the labeled population throughout the cell cycle followed (Table  2 ). All the clones incorporated BrdU to approximately the same extent during the pulse and cell progression, out of S into G2 phase, was similar in all cases. However, the reappearance of BrdU-positive cells was much faster in wt hTERT-infected cells (both at early and at late passages) than in mt hTERT-HA-or control-infected cells. The wt hTERT-infected cells required about 20 h to progress through the cell cycle, compared to about 40 h for hTERT-HA-or control virus-infected cells. The cells were then exposed to BrdU for 24 and 48 h, to evaluate the proliferation behavior of the whole population. As reported in Table  2 , after 24 h of BrdU exposure, about 100% of wthTERT-infected cells both at early and late passages were positive. On the contrary, the percentage of control and mt hTERT-HA BrdU positive cells was about 70% after 48 h of BrdU exposure, indicating that a 30% of cell population is unable to progress through cell cycle.
To strengthen the data demonstrating a critical role of hTERT in M14 cell proliferation, M14 cells were transfected with a retroviral plasmids carrying either the catalytically inactive dominant negative form of hTERT (DN-hTERT) or the gene for the puromycin resistance. Three DN-hTERT clones showing about seven times lower telomerase activity than control cells (data not shown) were used. Figure 3 shows the growth curves of the M14 parental line, MV3 control clone and MDN2, MDN4, MDN16 DN-hTERT clones. It is evident that after day 2 of growth the DN-hTERT clones showed a reduced cell proliferation with a saturation density of about 1610 6 cells compared to about 2.5610 6 for the control cells. To investigate whether restoration of telomerase in the c-Myc low-expressing clones altered the apoptotic program, TUNEL assay was performed. As shown in Figure 4 , apoptosis was detected in cells infected with the control and hTERT-HA viruses or with the wt hTERT virus analysed at early culture passages, but not in those infected with the latter virus analysed at late passages. The percentage of apoptotic cells, calculated at day 6 of culture, was about 45% in the ®rst three population, but was reduced to less than 5% in cells infected with wt hTERT at late passages.
Up-regulation of hTERT increases the tumorigenic ability of the c-Myc low-expressing clones
To evaluate whether restoration of telomerase activity aected tumorigenicity, c-Myc low-expressing clones infected with the wt hTERT and control viruses, were injected in nude mice. Before injection, c-Myc protein expression was evaluated. As summarized in Table 3 , no increase in c-Myc expression was found in the wt hTERT-infected cells analysed at early passages (MAS51/T E , MAS53/T E ) and in the control virusinfected cells (MAS51/V L , MAS53/V L ), the optical density being about 1.5 for the dierent lines. However, a signi®cant increase in the levels of the cMyc protein was evident in cells infected with wt hTERT when analysed at late passages.
Expression of wt hTERT was also able to enhance the tumorigenicity of the cells. Injection of 1610 6 cells infected with the control virus induced tumors in only four out of 12 mice and smaller inocula were negative for this aspect (Table 3 To ensure that the increase in tumorigenicity observed in wt hTERT-infected cells at early in vitro passages was not due to an increase in c-Myc protein expression or alteration in apoptosis during in vivo growth, immuno-staining for c-Myc and TUNEL assay were performed in tumor specimens. The analysis was carried out in tumors originating from 1610 6 hTERTinfected cells because all mice developed tumors independently from the passages of clones inoculated. A strong nuclear immuno-reactivity for c-Myc was observed in MAS51/T L and MAS53/T L while no detectable positivity for c-Myc was revealed in the corresponding lines at early passages ( Figure 5A ). Moreover, a great number of apoptotic cells was observed in the clones at early passages compared to those at late passages ( Figure 5B ). These results clearly show that hTERT-infected cells maintain the phenotypic characteristic of the in vitro clones, demonstrating that the increased tumorigenicity in the hTERT transfectants at early passages is mainly due to telomerase activity and consequently telomeres length, although the high levels of c-Myc and reduction of apoptosis may contribute to the tumor take observed with decreasing inoculum size at late passage cells.
Discussion
The identi®cation of TERT as a Myc target gene led Wang et al. (1998) to hypothesize that telomerase activation may be one of the components which enable Myc to facilitate tumor formation. However, DePinho and coworkers showed that TERT is unable to substitute c-Myc in the transformation of primary rodent ®broblast (Greenberg et al., 1999b) . So far there are no data about the involvement of hTERT in the ability of c-Myc to modulate the malignant behavior of tumor cells.
Here, we report, for the ®rst time, that the reconstitution of telomerase function reverses the low tumorigenicity due to c-Myc down-regulation in three cellular clones derived from a highly tumorigenic human melanoma line.
We ®rstly found that the down-regulation of c-Myc in the M14 human melanoma cell line leads to a reduction of proliferation rate accompanied by an increase in apoptotic rate and a decrease in clonogenic ability. The in vitro biological properties correlate with a signi®cant decrease in tumorigenicity. These results are in agreement with our and other previous studies demonstrating a key role of c-myc in melanoma progression (Leonetti et al., 1996 (Leonetti et al., , 1999 Citro et al., 1998; Kraehn et al., 2001) .
Moreover, we found that the c-Myc low-expressing clones showed a decreased hTERT mRNA expression, telomerase activity and telomere length compared to the control clone and parental line. These results are consistent with a previous study demonstrating that exposure of three dierent human leukemic cell lines to antisense oligonucleotides targeted against c-myc mRNA results in down-regulation of telomerase activity (Fujimoto and Takahashi, 1997) . Coordinated expression of Myc and telomerase is also observed during mouse erytroleukemia cell dierentiation and in neuroblastoma (Greenberg et al., 1998; Hiyama et al., 1995) .
To investigate the potential involvement of telomerase in c-Myc-dependent tumorigenicity, telomerase activity was enhanced in the c-Myc low-expressing clones. Our data clearly demonstrate that the upregulation of telomerase activity restores the proliferation of the c-Myc low-expressing clones, thus indicating that c-Myc-mediated cell proliferation is modulated by this enzyme at least in this experimental model. The decreased cell proliferation induced by down-regulation of telomerase activity in M14 cells, strengthens the data supporting a critical role of hTERT in the proliferation of our experimental model. These results are in agreement with previous studies, which demonstrated that telomerase activity is associated with cell proliferation in normal cells and tumors (Greider, 1998; Autexier and Greider, 1996; Chadeneau et al., 1995) . Since expression of the mt hTERT-HA, which is catalytically active but unable to lengthen telomeres, did not enhance proliferation rate, as the wt enzyme did, it is tempting to speculate that telomere conformation may vary according to whether wt or biologically inactive hTERT is present in the cells. Therefore, the increase in cell proliferation, following hTERT up-regulation, could be a consequence of a stop in telomere shortening. Moreover, apoptosis caused by c-Myc down-regulation seems to be related to telomere dysfunction due to the lack of a mechanism that maintains telomeres. In fact, at early passages, when telomeres are short, the cells are still in a state of crisis and undergo apoptosis. On the contrary, at late passages, telomere lengthening, above a critically short threshold, confers an advantage to the cells by inhibiting apoptosis. Our data are consistent with results demonstrating that inhibition of telomerase in human immortal and tumor cells leads to progressive telomere shortening and cell death (Herbert et al., 1999; Zhang et al., 1999) . Proliferation rate and apoptosis are known to be involved in the regulation of tumorigenicity. Given that telomerase activity at early passages restores cell proliferation without aecting apoptotic rate, it is not surprising that hTERT upregulation restores only partially the tumorigenic potential of these populations. Indeed, the complete restoration of the tumorigenic potential in late passage cells is accompanied by telomere lengthening and signi®cant reduction in apoptotic cell death. Our data are in agreement with studies showing that telomerase de®cient mice, with short telomeres, are resistant to tumor development in multi-stage skin carcinogenesis (Gonzalez-Suarez et al., 2000a) , while increased epidermal tumors has been found in transgenic mice overexpressing mTERT in basal keratinocytes (Gonzalez-Suarez et al., 2001) .
Taken together, our results demonstrate that telomerase activity and telomere length are involved in the c-Myc-mediated tumorigenicity. These results are not in contrast with those demonstrating that TERT is not functionally equivalent in cellular transformation (Greenberg et al., 1999a) but it is possible that telomerase plays a crucial role only after c-Mycinduced transformation, indicating that the oncogenic capacity of c-myc requires the induction of TERT in addition to that of a number of other genes (Grandori and Eisenman, 1997) . Telomere stabilization, inhibition of apoptosis and complete restoration of tumorigenicity are associated with increase of c-Myc protein in wt hTERT-infected cells, indicating that c-Myc cooperates with telomere maintenance in a more aggressive phenotype. These results are in agreement with a recent study, which demonstrated that the extension of life span conferred by hTERT in normal human ®broblasts causes c-Myc activation (Wang et al., 2000) . Our data are consistent with studies indicating that, although the expression of telomerase alone does not lead to a tumorigenic phenotype (Morales et al., 1999; Jiang et al., 1999) , telomere maintenance by telomerase in vivo cooperates with additional oncogenic mutations to create a malignantly transformed clone (Hahn et al., 1999a) . This cooperating eect has also been observed in mice. A reduction in tumor formation was observed in late generation mice doubly null for the telomerase RNA component and INK4a tumor suppressor genes, and reactivation of telomerase restored the oncogenic potential (Greenberg et al., 1999b) . Moreover, p53 de®ciency cooperates with telomere dysfunction to accelerate carcinogenesis (Chin et al., 1999) .
In conclusion, our results demonstrate that c-Myc down-regulation reduces the tumorigenicity of M14 melanoma cells by inhibiting telomerase activity, and consequently indicate that the oncogenic activity of cmyc is associated with its ability to activate the expression of the catalytic subunit of the enzyme. 
Materials and methods
Cells, virus and transfection experiments
The M14 human melanoma cell line, the MN2 control clone expressing only a selectable marker, and three clones expressing low levels of c-Myc, were obtained previously (Biroccio et al., 2001) . Brie¯y, M14 cells were transfected with an expression vector carrying the c-myc gene (exon 2+exon 3) cloned in antisense orientation. The selected clones, MAS51, MAS53 and MAS57, showing about eight times lower c-Myc protein expression compared to MN2 and M14 cells, were maintained in vitro as previously described and employed at the eighth passage after isolation. Before each experiment, in vitro growth and c-Myc expression were assessed.
M14 parental line was also transfected with retroviral plasmids carrying either the catalytically inactive dominant negative form of hTERT (pBabe/DN-hTERT) or the puromycin resistance only (pBabe) Transfection were performed as previously reported (Biroccio et al., 2001) . Three MDN4 and MDN16) , showing about seven times lower telomerase activity than parental (M14) or control cells (MV3) were used for the experiments.
To obtain the retroviruses, the Phoenix amphotropic packaging line was transfected, by the calcium phosphate method (Profection mammalian transfection system calcium phosphate, Promega Corporation, Madison, USA), with the retroviral plasmids pLXSP-hTERT (carrying the wild-type hTERT cDNA), pLXSP-hTERT-HA (carrying the mutant hemagglutinin-tagged hTERT which is catalytically active but unable to maintain telomeres, Counter et al., 1998) or pLXSP (encoding only the gene for the puromycin resistance). Transfected cells were incubated for 48 h at 378C for virus production. The virus-containing medium was collected and ®ltered (0.22 mm ®lter) to remove packaging cells. Target cells were infected overnight with the virus supernatant supplemented with 4 mg/ml polybrene (Sigma, Milano, Italy) and the infected cells were selected for 48 h with puromycin (1 mg/ ml; Sigma). The MAS51 and MAS53 clones infected with pLXSP-hTERT and pLXSP retroviruses were analysed at early (2nd ± 4th) and late (12th ± 15th) passages after infection, while those infected with pLXSP-hTERT-HA were analysed only at late passages.
Cell growth was assessed by seeding 5610 4 cells in 60-mm Petri plates (Nunc, Mascia Brunelli, Milano, Italy) . Cell counts (Coulter Counter, Kontron Instruments, Milano, Italy) and viability (Trypan blue dye exclusion) were determined daily, from day 1 to day 8 of culture. To evaluate cell colony-forming ability, aliquots of each cell line were seeded into 60-mm plates and after 10 ± 12 days colonies were stained with 2% methylene blue in 95% ethanol and counted (450 cells equalled one colony).
Western blot
Western blot and detection were performed as previously reported (Leonetti et al., 1996) . Brie¯y, 40 mg of total proteins were loaded on denaturing SDS ± PAGE. Immunodetection of the c-Myc protein was performed by using a 1 : 1000 dilution of the anti c-myc monoclonal antibody (mAb) clone 9E10 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). To check the amount of proteins transferred to nitrocellulose membrane, b-actin was used as control. The relative amounts of the transferred proteins were quanti®ed by scanning the autoradiographic ®lms with a gel densitometer scanner (Bio-Rad, Milano, Italy) and normalized to the related b-actin amounts.
Bromodeoxyuridine (BrdU) labeling
Progression of cells through the cell cycle phases was analysed by Flow cytometry (Becton-Dickinson, San Jose, CA, USA) using BrdU (Becton-Dickinson) incorporation, as previously described (Biroccio et al., 2001) . Brie¯y, cells were pulsed with BrdU at a ®nal concentration of 10 mM for 15 min (0 h), and after the appropriate intervals in BrdU free-medium (from 4 to 44 h) the DNA was denatured. Long exposure to BrdU (24 and 48 h) was also performed and the analysis was carried out at the end of BrdU labeling. Cells were then incubated with 2 mg/ml of mouse anti-BrdU (clone BMC 9318, Roche Diagnostics Corp. Indianapolis, IN, USA) for 30 min at room temperature, and the BrdU-positive cells were revealed with FITC-conjugated anti-mouse mAb (1 : 20, Dako, SA, Glostrup, Denmark).
Terminal deoxynucleotide transferase [TdT]-mediated dUTP nick-end labeling (TUNEL)
Detection of apoptosis in cytospin preparation and in formalin-®xed, paran-embedded tumor tissues was performed by TUNEL assay using the ApopDETEK in situ apoptosis detection kit (Enzo Diagnostic, NY, USA). Fifty ml of TUNEL reaction mixture was applied to the cytospin preparation or to deparanated and rehydrated tumor section and the slides were incubated for 45 min at 378C. Incorporated Bio-16-dUTP was then stained with streptavidin-biotinylated horseradish peroxidase complex and visualized by using diaminobenzidine as chromogen. The percentage of apoptotic cells was determined by microscopic examination of TUNEL-treated slide at 6200. For each slide, ®ve ®elds were examined and 100 cells in each ®eld were counted. Tumorigenicity CD-1 male nude (nu/nu) mice, 6 ± 8 weeks old and weighing 22 ± 24 g, were purchased from Charles River Laboratories (Calco, Italy). All procedures involving animals and their care were as previously described (Leonetti et al., 1996) . To assess tumorigenicity, dierent numbers of tumor cells (from 8610 2 to 1610 6 /mouse) were injected i.m. Animals (12 for each group) were observed daily to establish tumor take, time of tumor appearance and tumor weight (Leonetti et al., 1996) . Sixty days after tumor implant, mice were sacri®ced and tumors excised to evaluate c-Myc expression and apoptosis.
Reverse transcriptase-polymerase chain reaction (RT ± PCR) Total RNA was isolated by Trizol (Gibco) following standard protocol. First-strand cDNA synthesis and ampli®cation of speci®c DNA sequences were performed by using RNA PCR Kit, according to the manufacturer's instructions (Perkin Elmer Cetus, Emeryville, USA). Brie¯y, 2 mg of total RNA were used for cDNA synthesis using oligo(dT) priming in the presence of Moloney murine leukaemia virus reverse transcriptase. hTERT cDNA was ampli®ed for 30 cycles (958C for 30 s, 558C for 30 s and 728C for 30 s) using the following primers: 5'-CGGAAGAGTGTCTGGAGCAA-3' and 5'-GGATGAAGCGGAGTCTGGA-3'. The expression of aldolase was used as an internal standard for RNA integrity.
Telomeric repeat amplification protocol (TRAP)
Telomerase enzyme activity was measured with the PCRbased TRAP kit (Intergen Company, Oxford, UK), according to the manufacturer's instruction. To de®ne the sensitivity of the method and the semi-quantitative relationship between protein concentration and ladder band intensity, dierent amounts of protein extract (from 0.1 to 2 mg) were used for each cell line and for all assays. In all cases reaction products were ampli®ed in the presence of a 36 bp internal TRAP assay standard (ITAS), and each extract was tested for heat sensitivity. Each set of TRAP assay included a control reaction without extract.
Southern blot
Total DNA was isolated using standard procedure. For each sample, 10 mg of DNA were digested with 40 units of Hinf1 and electrophoresed on 0.8% agarose gel. The gel was denatured, neutralized, transferred to a nylon membrane (Hybond N, Amersham International, Buckinghamshire, UK) and the DNA cross-linked with ultraviolet light. The membrane was hybridized with 5'-end g-32 P-deoxyadenosine triphosphate-labeled telomeric oligonucleotide probe (TTAGGG) 3 at 428C for 2 h in a rapid hybridization buer (QuikHyb Hybridization Solution, Stratagene, La Jolla, CA, USA). After washing, the ®lters were autoradiographed (Hyper®lm-MP; Amersham) with an intensifying screen at 7808C for 24 h. The autoradiographs were scanned and mean telomere length was calculated as reported by Harley et al. (1990) .
Immuno-histochemistry
Immuno-histochemistry staining was performed as previously described (Leonetti et al., 1999) . The c-Myc protein was detected with the 9E11 mAb (Novocastra, Newcastle, UK). To improve the staining pattern, heat-induced epitopes retrieval in a water bath (968C in 10 mmol/L citrate buer pH 6.0 for 40 min) and Trypsin digestion (0.2 g Trypsin 250 and 0.2 g calcium chloride in the 200 ml of TBS, for 30 min at 378C) were carried out. The sections were incubated with primary antibodies (dilution of 1 : 100) for 60 min at room temperature and the reaction visualized by using a sensitive streptavidin-biotin immunoperoxidase system (LSAB kit, Dako) and a 3 amino-9-ethyl carbazole solution (Dako) as chromogenic substrate. 
